These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29871738)

  • 1. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.
    Rodríguez-Jiménez P; Mir-Viladrich I; Chicharro P; Solano-López G; López-Longo FJ; Taxonera C; Sánchez-Martínez P; Martínez-Lacasa X; García-Gasalla M; Dorca J; Arias-Guillén M; García-García JM; Dauden E
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):584-601. PubMed ID: 29871738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment.
    Mir Viladrich I; Daudén Tello E; Solano-López G; López Longo FJ; Taxonera Samso C; Sánchez Martínez P; Martínez Lacasa X; García Gasalla M; Dorca Sargatal J; Arias-Guillén M; García García JM
    Arch Bronconeumol; 2016 Jan; 52(1):36-45. PubMed ID: 26187708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary leprosy infection in a patient with psoriasis during treatment with infliximab.
    Teixeira FM; Vasconcelos LM; Rola Cde A; Prata de Almeida TL; Valença JT; Nagao-Dias AT
    J Clin Rheumatol; 2011 Aug; 17(5):269-71. PubMed ID: 21778902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis in the age of biologic therapy.
    Hernandez C; Cetner AS; Jordan JE; Puangsuvan SN; Robinson JK
    J Am Acad Dermatol; 2008 Sep; 59(3):363-80; quiz 382-4. PubMed ID: 18694676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relevance of diagnostic criteria for latent tuberculosis before initiation of TNF-alpha inhibitors in psoriasis patients].
    Goujon C; Gormand F; Gunera-Saad N; Dahel K; Vial T; Nicolas JF
    Ann Dermatol Venereol; 2010; 137(6-7):437-43. PubMed ID: 20620572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications.
    Ellis A; Khanna U; Galadari A; Fernandez AP
    J Am Acad Dermatol; 2020 Jul; 83(1):246-248. PubMed ID: 31940465
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
    Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
    Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
    Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.
    Bieber J; Kavanaugh A
    Rheum Dis Clin North Am; 2004 May; 30(2):257-70, v. PubMed ID: 15172039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside.
    Xie X; Li F; Chen JW; Wang J
    J Microbiol Immunol Infect; 2014 Aug; 47(4):268-74. PubMed ID: 23727394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
    Goletti D; Petrone L; Ippolito G; Niccoli L; Nannini C; Cantini F
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):501-512. PubMed ID: 29848120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome.
    Rivoisy C; Amrouche L; Carcelain G; Séréni D; Bourgarit A
    Joint Bone Spine; 2011 May; 78(3):312-5. PubMed ID: 21334948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
    Gisondi P; Pezzolo E; Lo Cascio G; Girolomoni G
    Br J Dermatol; 2014 Oct; 171(4):884-90. PubMed ID: 24863903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis infections and tumor necrosis factor alpha antagonists.
    Gan J; Manadan AM; Sequiera W; Block JA
    Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.